Paclitaxel saves rat heart allografts from rejection by inhibition of the primed anti-donor humoral and cellular immune response: implications for transplant patients with cancer

Tange, Stefan and Scherer, Marcus N. and Graeb, Christian and Andrassy, Joachim and Justl, Martin and Frank, Erika and Jauch, Karl-Walter and Geissler, Edward K. (2003) Paclitaxel saves rat heart allografts from rejection by inhibition of the primed anti-donor humoral and cellular immune response: implications for transplant patients with cancer. TRANSPLANT INTERNATIONAL, 16 (7). pp. 471-475. ISSN 0934-0874

Full text not available from this repository. (Request a copy)

Abstract

Paclitaxel is an anti-neoplastic drug that was recently shown also to have immunosuppressive properties in nairat heart transplant recipients. Here, we tested whether paclitaxel could also effectively reverse an ongoing immune response in transplant recipients. We therefore used a model in which Lewis rat recipients receiving ACI rat heterotopic heart allografts were: (1) untreated, or treated with either (2) paclitaxel or (3) cyclosporine, starting 5 days after transplantation. Allograft survival was determined in one group, and in a second group cytotoxic T-lymphocyte (CTL) responses were determined and serum anti-donor cytotoxic antibody levels were measured. Results showed that paclitaxel was as effective as cyclosporine in saving recipients from imminent allograft rejection. Immunologically, paclitaxel reduced the allogeneic-CTL response, but most impressively, the cytotoxic antibody response was nearly eliminated in saved recipients. Therefore, paclitaxel's immunosuppressive properties, along with its known effectiveness against a wide variety of tumors, makes it potentially useful for the simultaneous treatment of rejection and neoplasms in cases of transplant-related cancer.

Item Type: Article
Uncontrolled Keywords: CLASS-I ANTIGEN; BRONCHIOLOALVEOLAR CARCINOMA; APOPTOSIS; STIMULATION; LYMPHOCYTES; PATHWAY; KINASE; CELLS; TAXOL; LUNGS; paclitaxel; post-transplant malignancy; antibody response; cytotoxic T lymphocytes; immunosuppression; heart transplantation
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Chirurgie
Depositing User: Dr. Gernot Deinzer
Date Deposited: 08 Sep 2021 09:46
Last Modified: 08 Sep 2021 09:46
URI: https://pred.uni-regensburg.de/id/eprint/38878

Actions (login required)

View Item View Item